Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis
- PMID: 23871824
- DOI: 10.1016/j.vaccine.2013.07.014
Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis
Abstract
Background: An estimated 4% of global child deaths (approximately 300,000 deaths) were attributed to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public finance of rotavirus vaccination in these two countries could substantially decrease child mortality and also reduce rotavirus-related hospitalizations, prevent health-related impoverishment and bring significant cost savings to households.
Methods: We use a methodology of 'extended cost-effectiveness analysis' (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. We measure program impact along four dimensions: 1) rotavirus deaths averted; 2) household expenditures averted; 3) financial risk protection afforded; 4) distributional consequences across the wealth strata of the country populations.
Results: In India and Ethiopia, the program would lead to a substantial decrease in rotavirus deaths, mainly among the poorer; it would reduce household expenditures across all income groups and it would effectively provide financial risk protection, mostly concentrated among the poorest. Potential indirect benefits of vaccination (herd immunity) would increase program benefits among all income groups, whereas potentially decreased vaccine efficacy among poorer households would reduce the equity benefits of the program.
Conclusions: Our approach incorporates financial risk protection and distributional consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought.
Keywords: Child health; Equity; Extended cost-effectiveness analysis (ECEA); Financial risk protection; Low- and middle-income settings; Rotavirus; Vaccination.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.Vaccine. 2012 Apr 27;30 Suppl 1:A15-23. doi: 10.1016/j.vaccine.2012.01.018. Vaccine. 2012. PMID: 22520124
-
Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities.Vaccine. 2014 Aug 11;32 Suppl 1:A140-50. doi: 10.1016/j.vaccine.2014.05.073. Vaccine. 2014. PMID: 25091669
-
Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.Pediatr Infect Dis J. 2015 Jul;34(7):e176-84. doi: 10.1097/INF.0000000000000727. Pediatr Infect Dis J. 2015. PMID: 25923424
-
Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27. doi: 10.1086/605026. J Infect Dis. 2009. PMID: 19817595 Review.
-
Health Policy Analysis: Applications of Extended Cost-Effectiveness Analysis Methodology in Disease Control Priorities, Third Edition.In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, Nugent R, editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 27. Chapter 8. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, Nugent R, editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 27. Chapter 8. PMID: 30212165 Free Books & Documents. Review.
Cited by
-
Facilitators and barriers for use of rotavirus vaccine amongst various stakeholders and its implications for Indian context - A systematic review.Hum Vaccin Immunother. 2018;14(11):2760-2767. doi: 10.1080/21645515.2018.1489190. Epub 2018 Jul 12. Hum Vaccin Immunother. 2018. PMID: 29913110 Free PMC article.
-
Point-of-care testing and treatment of sexually transmitted and genital infections during pregnancy in Papua New Guinea (WANTAIM trial): protocol for an economic evaluation alongside a cluster-randomised trial.BMJ Open. 2021 Aug 12;11(8):e046308. doi: 10.1136/bmjopen-2020-046308. BMJ Open. 2021. PMID: 34385236 Free PMC article.
-
Health Gains and Financial Protection from Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from an Extended Cost-Effectiveness Analysis.PLoS One. 2015 Dec 9;10(12):e0142691. doi: 10.1371/journal.pone.0142691. eCollection 2015. PLoS One. 2015. PMID: 26650078 Free PMC article.
-
Methods to promote equity in health resource allocation in low- and middle-income countries: an overview.Global Health. 2020 Jan 13;16(1):6. doi: 10.1186/s12992-019-0537-z. Global Health. 2020. PMID: 31931823 Free PMC article. Review.
-
Challenges for modelling interventions for future pandemics.Epidemics. 2022 Mar;38:100546. doi: 10.1016/j.epidem.2022.100546. Epub 2022 Feb 11. Epidemics. 2022. PMID: 35183834 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical